Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Understand the source comparison

Peptides and Metformin Synergy Timing Protocol: Research Compound Comparison

GH Secretagogues (CJC-1295, MK-677, Ipamorelin) AMPK activation increases fat oxidation from GH-stimulated lipolysis; reduces lipotoxic insulin resistance Metformin 30–60 min before peptide injection; fasted state preferred 25–40% greater visceral fat loss; 15

No winner is assigned.

This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.

  • GH Secretagogues (CJC-1295, MK-677, Ipamorelin)
  • AMPK activation increases fat oxidation from GH-stimulated lipolysis; reduces lipotoxic insulin resistance
  • Metformin 30–60 min before peptide injection; fasted state preferred
  • 25–40% greater visceral fat loss; 15–20% improved insulin sensitivity vs peptide alone
  • Strongest synergy. GH elevates FFA and metformin ensures oxidation rather than re-esterification
  • GLP-1 Agonists (Semaglutide analogs)
  • Metformin suppresses hepatic glucose output through complementary AMPK pathway; additive A1C reduction
  • Metformin 30 min before GLP-1 dose; co-administration acceptable for convenience
  • 15–22% greater A1C reduction; 10–15% additional weight loss at 24 weeks
  • Well-documented clinical synergy. Both reduce gluconeogenesis through different mechanisms
  • Metabolic Research Peptides (Tesofensine, SLU PP 332)
  • Enhanced mitochondrial fat oxidation and insulin receptor sensitization align with peptide lipolytic effects
  • Metformin 30–60 min before peptide; morning dosing maximizes fasted fat oxidation window
  • 20–35% greater fat loss; improved nutrient partitioning during refeeds
  • Mechanistic alignment strong but limited human data. Synergy likely based on pathway overlap
  • Tissue Repair Peptides (BPC-157, TB-500)
  • No direct metabolic synergy. Mechanisms independent
  • Timing irrelevant; dose as convenient
  • No measurable enhancement expected
  • Minimal benefit. Metformin offers no advantage for localized anti-inflammatory or angiogenic effects
  • Nootropic Peptides (Dihexa, Cerebrolysin, P21)
  • No mechanistic overlap. BDNF and neurotrophic pathways unaffected by AMPK modulation
  • Timing irrelevant
  • No enhancement
  • Zero synergy. These pathways don't intersect

Related resources

More comparisons